According to Acorda Therapeutics, Esteve Pharmaceuticals has launched Acorda’s Inbrija inhaled dry powder levodopa in Spain. Acorda announced the Spanish distribution deal with Esteve in July 2021. Inbrija DPI has been approved in Europe for the treatment of OFF periods in Parkinson’s disease since 2019.
Acorda President and CEO Ron Cohen said, “Today’s announcement is great news for people in Spain who are living with Parkinson’s and suffer from OFF periods. Esteve is a leader in commercializing central nervous system therapeutics in Spain. They will be educating neurologists about providing patients with the ability to treat their OFF periods on-demand with Inbrija.”
Esteve also has marketing rights to Inbrija in Germany and launched the DPI there in June 2022. In addition, Biopas Laboratories acquired rights to Inbrija in nine Latin American countries, including Brazil and Mexico, in May 2022.
In the US, Inbrija was approved by the FDA in December 2018, and Acorda launched the DPI in the US in February 2019. Catalent purchased the facility that manufactures Inbrija from Acorda in January 2021.
Read the Acorda Therapeutics press release.
